|
End-of-day quote
Pakistan S.E.
2026-09-10
|
5-day change | 1st Jan Change | ||
| 305.50 PKR | -2.50% |
|
-6.20% | -21.62% |
Company Valuation: GlaxoSmithKline Pakistan Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Market Cap 1 | 126,403 | 124,132 | 97,292 | - | - |
| Change | - | -1.8% | -21.62% | - | - |
| Enterprise Value (EV) | 126,403 | 124,132 | 97,292 | 97,292 | 97,292 |
| Change | - | -1.8% | -21.62% | 0% | 0% |
| P/E | 19.3x | 12.4x | 9.2x | 7.64x | 6.81x |
| PBR | - | 3.69x | 2.55x | 2.16x | 1.88x |
| PEG | - | 0.2x | 1.67x | 0.4x | 0.6x |
| Capitalization / Revenue | - | 1.88x | 1.41x | 1.3x | 1.19x |
| EV / Revenue | - | 0x | 1.41x | 1.3x | 1.19x |
| EV / EBITDA | - | - | - | - | - |
| EV / EBIT | - | - | - | - | - |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Dividend per Share 2 | - | 17 | 18.04 | 20.81 | 23 |
| Rate of return | - | 4.36% | 5.91% | 6.81% | 7.53% |
| EPS 2 | 20.52 | 31.48 | 33.21 | 39.96 | 44.85 |
| Distribution rate | - | 54% | 54.3% | 52.1% | 51.3% |
| Net sales 1 | - | 65,901 | 68,813 | 74,577 | 81,779 |
| EBITDA | - | - | - | - | - |
| EBIT | - | - | - | - | - |
| Net income 1 | 6,536 | 10,025 | 10,490 | 12,420 | 14,268 |
| Net Debt | - | - | - | - | - |
| Reference price 2 | 396.91 | 389.78 | 305.50 | 305.50 | 305.50 |
| Nbr of stocks (in thousands) | 318,467 | 318,467 | 318,467 | - | - |
| Announcement Date | 3/24/25 | 3/26/26 | - | - | - |
1PKR in Million2PKR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 9.43x | - | - | 5.76% | 360M | |
| 32x | 11.63x | 23.59x | 0.62% | 1,002B | |
| 28.37x | 6.53x | 17.91x | 2.01% | 644B | |
| 32.13x | 7.46x | 15.49x | 2.73% | 443B | |
| 18.9x | 4.61x | 11.42x | 2.88% | 343B | |
| 19.46x | 5.11x | 12.69x | 3.2% | 262B | |
| 20.29x | 4.17x | 11.93x | 2.12% | 245B | |
| 24.75x | 6.5x | 11.57x | 2.58% | 212B | |
| 12.86x | 4.67x | 9.75x | 3.91% | 199B | |
| -44.5x | 6.43x | 25.11x | 2.26% | 181B | |
| Average | 15.37x | 6.35x | 15.50x | 2.81% | 353B | |
| Weighted average by Cap. | 22.91x | 7.53x | 17.31x | 2.04% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GLAXO Stock
- Valuation GlaxoSmithKline Pakistan Limited
Select your edition
All financial news and data tailored to specific country editions
